Research
Hormonal
Exercise training mobilizes endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) from the bone marrow, promoting vascular regeneration and endothelial repair.
Exercise helps your body repair blood vessel damage by releasing stem cells from your bone marrow that can fix the lining of your arteries.
GoodSupportsHIGH confidence
Numerous studies have provided strong evidence that ET mobilizes EPCs and MSCs from the bone marrow (BM) while improving the functional capacity of the cells.
Why this rating
Supported by numerous studies and gene targeting experiments cited.
Source
Role of exercise in the prevention of cardiovascular disease: results, mechanisms, and new perspectives
Gerhard Schüler et al. · European Heart Journal · 2013
DOI 10.1093/eurheartj/eht111
narrative_reviewCited 244×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Low patient compliance with exercise training programs is a major drawback limiting the effectiveness of exercise as a therapeutic intervention for cardiovascular disease prevention at the population level.Strong
- Regular exercise training significantly reduces the risk of cardiovascular disease mortality and all-cause mortality in both primary and secondary prevention contexts, with benefits observed even at low doses (e.g., 15 minutes/day).Good
- Exercise training improves endothelial function and nitric oxide (NO) bioavailability by upregulating eNOS activity through shear stress mechanisms, thereby reducing peripheral resistance and improving vascular perfusion.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →